Scandinavian Tobacco Group A/S reports strong Q2 results and raises full year guidance
Copenhagen, 19 August 2021
Interim report, 1 January - 30 June 2021
Scandinavian Tobacco Group A/S reports strong Q2 results and raises full year guidance
In the second quarter of 2021, Scandinavian Tobacco Group delivered a strong organic growth in net sales and EBITDA. The results were primarily driven by a continued high demand in handmade cigars in the US, a favourable market mix and synergies from the integration of Agio Cigars. The second quarter of last year was negatively impacted by the early phases of the COVID-19 pandemic making comparisons relatively easy.
- Net sales were DKK 2,156 million (DKK 2,097 million) with 7.5% organic growth.
- EBITDA before special items was DKK 606 million (DKK 489 million) with 20.8% organic growth. The EBITDA margin was 28.1% (23.3%).
- Adjusted Earnings Per Share (EPS) were DKK 4.1 (DKK 3.0).
- Free cash flow before acquisitions was DKK 434 million (DKK 425 million).
- Return on Invested Capital was 12.3% (7.6%).
- In the first 6 months of 2021, net sales grew by 9.8% organically to DKK 4,039 million (DKK 3,852 million), and EBITDA before special items grew by 32.6% organically to DKK 1,133 million (DKK 815 million) with free cash flow before acquisitions stable at DKK 523 million (DKK 547 million).
CEO Niels Frederiksen: “We deliver a strong quarterly performance with growth in both net sales and EBITDA driven by strong sales of handmade cigars in the US and a favorable mix. We expect continued high demand for handmade cigars for the rest of the year and we are raising our financial expectations for 2021 to reflect that. Additionally, we continue to implement our “Rolling towards 2025” strategy and show good progress on the transformation of the company”.
The current high consumption of handmade cigars in the US combined with a strong market mix have driven the extraordinarily strong net sales growth during the first half of 2021. Growth is still expected to taper off during the second half of the year as year-on-year comparisons are more difficult especially in the third quarter and as the market mix is expected to normalize somewhat. However, the full year is now expected to be stronger than previously anticipated, although the risks remain higher than normal due to COVID-19.
The financial outlook for 2021 is revised to:
- EBITDA: Organic growth in the range of 16%-20% (from 12%-18%)
- Free cash flow before acquisitions: In the range of DKK 1.0-1.3 billion
- Adjusted Earnings Per Share >35% increase (from >25% increase)
For further information, please contact:
Investors: Torben Sand, Head of IR, phone +45 5084 7222 or firstname.lastname@example.org
Media: Simon Mehl Augustesen, Director of Group Communications, phone: +1 484-379-8725 or email@example.com
A conference call will be held on 25 August 2021 at 10.00 CEST. Dial-in information and an accompanying presentation will be available at investor.st-group.com around 09:00 CEST.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer19.9.2021 13:30:00 CEST | Press release
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting2 Kisqali plus letrozole achieved median OS of over five years (63.9 months), a survival benefit of over 12 months vs. placebo plus letrozole in postmenopausal women (HR=0.76; p=0.004)2 Kisqali is the only CDK4/6 inhibitor with proven OS benefit across all three Phase III trials of the MONALEESA program with different endocrine therapy partners, regardless of menopausal status or line of therapy2-4 MONALEESA-2 OS data to be presented at ESMO Congress 2021 as a late-breaker in an oral session The digital press release with multimedia content can be accessed here: Basel, September 19, 2021 — Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combinati
Hypefactors announces launch of 4th generation Reputation AI18.9.2021 10:37:51 CEST | Press release
Copenhagen, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Announcement no. 13-2021 Inside Information Copenhagen, 18. September 2021 The SaaS company Hypefactors, that delivers a unified solution for media intelligence and reputation tracking, will launch its next generation Reputation AI (artificial intelligence) on September 20, 2021. Through algorithmic advances in machine learning, as well as drastically increased data curated by a team of in-house recruited linguists with diverse language and cultural backgrounds, Hypefactors incorporates the latest scientific advances in natural language processing to deliver unprecedented accuracy, precision and automation to commercial end-users. AI-assisted reputation tracking is a core feature of Hypefactors and enables large scale tracking from social media, news websites, tv, radio and reviews across the world. These real-time reputation insights can reveal early-stage opportunities (e.g. GameStop media hype), and/or defensively as an on-going protect
Repurchase of shares in Millicom17.9.2021 23:00:00 CEST | Press release
Repurchase of shares in Millicom Luxembourg, September17, 2021 - During the period September 9, 2021 – September 15, 2021, Millicom repurchased a total of 131,559 of its Swedish Depository Receipts (SDRs), hereinafter referred to as shares within the framework of the repurchase program announced on July 29, 2021, details of which are shown in the table below. DateNumber of shares repurchasedWeighted average repurchaseprice (SEK) excluding commissionsTotal daily transaction value (SEK), excluding commissions 09/09/2021 15,000 322.6863 4,840,294.50 10/09/2021 30,000 322.1097 9,663,291.00 13/09/2021 17,974 322.3942 5,794,713.35 14/09/2021 15,725 321.5394 5,056,207.07 15/09/2021 52,860 314.4509 16,621,874.57 All purchases were carried out on Nasdaq Stockholm by Citigroup Global Markets Limited on behalf of Millicom. Following the purchases, as of September 15, 2021, Millicom holds 792,425 treasury shares. The total number of shares outstanding in Millicom is 101,739,217. The repurchase pro
Palette Life Sciences lanserar ny varumärkeswebbplats med USA:s portfölj17.9.2021 18:09:14 CEST | Pressemelding
Varumärkesuppdatering för USA och globala kommersiella produkter för behandling av ouppfyllda medicinska behov SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett helt integrerat globalt företag inom biovetenskap som arbetar för att förbättra patientutfall, lanserade idag sin nyligen uppdaterade webbplats Palettelifesciences.com. Webbplatsen har ett uppdaterat företagsvarumärke som stöder alla produkter i Palette Life Sciences-portföljen, och som fokuserar på minimalt invasiva behandlingar inriktade på ouppfyllda medicinska behov vid strålbehandling och interventionella onkologiska ingrepp, urologiska/urogynekologiska sjukdomar och kolorektala tillstånd. ”Vi inom Palette är stolta över vår förstklassiga produktportfölj som ger hopp åt dem med ouppfyllda medicinska behov”, säger Per G. Langö, Chief Executive Officer och Board Director för Palette Life Sciences. ”När vi bytte varumärke på vår webbplats övervägde vi hur vi bäst
Prosafe SE: bp charters Safe Zephyrus in 202217.9.2021 17:40:15 CEST | Press release
BP Exploration Operating Company Limited ('bp') has chartered the Safe Zephyrus to provide gangway connected operations to support the Seagull project at the ETAP central processing facility in the UK North Sea. The firm duration of the contract, starting Q1 2022, is 10 months with up to four months of options. The Safe Zephyrus is one of the world's most advanced and versatile accommodation vessels, complying with stringent rules in both UK and Norway and with a strong focus on reducing emissions by optimising the engine load. The value of the contract firm duration is USD 35.5 million, and the firm duration including options value is USD 49.3 million. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com 17 September 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-23BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 520, SE0014694659, 2027-09-15 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-09-23Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 146: 700 mln SEK +/-350 mln SEK 581: 500 mln SEK +/-250 mln SEK 520: 600 mln SEK +/-300 mln SEK 2312: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 400 mln SEK per bid 1591: 1900 mln SEK per bid 146: 700 mln SEK per bid 581: 500 mln SEK per bid 520: 600 mln SEK per bid 2312: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-24BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2021-09-24Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 500 mln SEK +/-250 mln SEK 1053: 750 mln SEK +/-350 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 500 mln SEK per bid 1053: 750 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-28Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-09-17 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c